|
|
Volumn 4, Issue 1, 2012, Pages 1-3
|
|
Which are the antibodies to watch in 2012?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BLOOD CLOTTING FACTOR 8;
BLOOD CLOTTING FACTOR 9;
ELOTUZUMAB;
EPRATUZUMAB;
ETANERCEPT;
FACTOR 8 FC FUSION PROTEIN;
FACTOR 9 FC FUSION PROTEIN;
FARLETUZUMAB;
FC RECEPTOR;
GIRENTUXIMAB;
HYBRID PROTEIN;
INFLIXIMAB;
INOTUZUMAB OZOGAMICIN;
ITOLIZUMAB;
MEPOLIZUMAB;
MONOCLONAL ANTIBODY;
NAPTUMOMAB ESTAFENATOX;
NECITUMUMAB;
OBINUTUZUMAB;
OCRELIZUMAB;
PERTUZUMAB;
RAMUCIRUMAB;
RITUXIMAB;
SARILUMAB;
TABALUMAB;
TRASTUZUMAB;
TRASTUZUMAB EMTANSINE;
TREBANANIB;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VEDOLIZUMAB;
ZANOLIMUMAB;
ADVANCED CANCER;
ALZHEIMER DISEASE;
ANKYLOSING SPONDYLITIS;
ASTHMA;
AUTOIMMUNE DISEASE;
BREAST CANCER;
CANCER THERAPY;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL EVALUATION;
COLORECTAL CANCER;
CROHN DISEASE;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG MECHANISM;
DRUG SCREENING;
EDITORIAL;
HYPEREOSINOPHILIC SYNDROME;
KIDNEY CARCINOMA;
LARGE CELL LYMPHOMA;
LIVER CELL CARCINOMA;
LUNG ADENOCARCINOMA;
LUNG NON SMALL CELL CANCER;
MULTIPLE MYELOMA;
MULTIPLE SCLEROSIS;
MYCOSIS FUNGOIDES;
NONHODGKIN LYMPHOMA;
OVARY CANCER;
PERITONEUM CANCER;
PHASE 3 CLINICAL TRIAL (TOPIC);
PSORIASIS;
RHEUMATOID ARTHRITIS;
SEZARY SYNDROME;
STOMACH ADENOCARCINOMA;
SYSTEMIC LUPUS ERYTHEMATOSUS;
TREATMENT INDICATION;
ULCERATIVE COLITIS;
UTERINE TUBE CARCINOMA;
ALZHEIMER DISEASE;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS, PHASE III AS TOPIC;
HEMOPHILIA A;
HUMANS;
IMMUNE SYSTEM DISEASES;
NEOPLASMS;
|
|
EID: 84856800190
PISSN: 19420862
EISSN: 19420870
Source Type: Journal
DOI: 10.4161/mabs.4.1.18719 Document Type: Editorial |
|
Times cited : (55)
|
|
References (0)
|
